The company intends to fund the acquisition using cash on hand and a new Term Loan credit facility. The transaction is anticipated to close in the first half of fiscal 2027, subject to customary closing conditions, including regulatory approval under the Hart-Scott Rodino Antitrust Improvements Act of 1976.
The acquisition supports Prestige’s long-term organic sales growth target of 2-3% and is expected to immediately improve the company’s gross and EBITDA margins.
Breathe Right has a strong financial profile, generating approximately $200 million in revenue and $95 million in EBITDA for the twelve months ending December 31, 2025.
Breathe Right accounts for about two-thirds of the revenue and profitability of the acquired portfolio and will become the largest brand in Prestige’s portfolio. The remaining portfolio includes Dimetapp® and Anbesol®, established brands in the children’s cold relief and oral pain relief categories, respectively.
“With its high consumer recognition, Breathe Right is a well-known, multi-use health product in the growing sleep and breathing improvement markets, offering potential for long-term brand development. Similar to our strategy with brands like Dramamine® in motion sickness, we are acquiring a brand that defines its category, providing a solid base for sustained growth,” said Ron Lombardi, Chairman, President, and CEO of Prestige Consumer Healthcare.
 has agreed to acquire the Breathe Right® brand and other assets from Foundation Consumer Healthcare for $1.045 billion, expected to close in the first half of fiscal 2027.){kind=link}